# Blood test could identify bacterial infections in newborns within 15 minutes
Researchers have developed a rapid blood test that distinguishes bacterial infections from viral ones in feverish infants, potentially eliminating unnecessary antibiotic use in hospitals. The test delivers results in 15 minutes, compared to traditional culture methods that require 24 to 48 hours.
Fever in hospitalized newborns triggers automatic antibiotic treatment because clinicians cannot quickly determine whether the infection stems from bacteria or viruses. Bacterial infections pose serious risks to infants, making caution medically prudent. However, viral infections typically resolve without intervention and do not require antibiotics. This diagnostic uncertainty leads physicians to administer broad-spectrum antibiotics to virtually every feverish infant admitted to neonatal intensive care units, even when the underlying infection is viral.
The consequences of this blanket approach extend beyond individual patients. Widespread antibiotic use in hospitals accelerates the development of antibiotic-resistant bacteria, a growing public health threat. Unnecessary exposure also disrupts the infant's developing microbiome, potentially affecting long-term health outcomes. The test addresses both concerns by enabling rapid bacterial identification.
The technology works by detecting biomarkers in blood that indicate bacterial versus viral infection. Bacterial infections trigger distinct immune responses characterized by specific protein patterns. The test identifies these signatures far faster than conventional culture methods, which remain the clinical gold standard but require pathogens to multiply sufficiently for identification.
The research appears in the New Scientist, though the specific research team, publishing journal, and host institution were not detailed in the available information. The test's development reflects growing momentum in rapid diagnostics for neonatal care, where speed directly impacts treatment decisions and patient outcomes.
Clinical implementation faces several hurdles. The test must prove reliable across diverse bacterial and viral pathogens. Validation studies in real hospital settings will determine whether the 15-minute timeframe holds up under routine conditions. Cost-effectiveness compared to current protocols remains unestablished. Healthcare systems must also develop protocols for acting on rapid test results when antibiotics have already been administered.
The technology builds on advances in biomarker detection and point-of-care diagnostics. Similar rapid tests have shown promise in adult populations for identifying sepsis and other serious infections. Adapting these platforms for neonatal use required optimizing sensitivity and specificity for smaller blood samples and the unique immune profiles of newborns.
Adoption would shift clinical practice significantly. If validated, hospitals could reserve antibiotics for confirmed bacterial infections while monitoring viral cases with supportive care alone. This targeted approach reduces antibiotic exposure while maintaining safety for infants with genuine bacterial threats.
The test represents a practical application of precision medicine in neonatology. Rather than treating all fevers identically, clinicians could base decisions on rapid, objective data. Widespread implementation could substantially reduce antibiotic use in neonatal intensive care units globally while improving outcomes through earlier identification of truly severe infections.